MA38403A1 - Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 - Google Patents

Nouveaux dérivés de pyrazole modulateurs specifiques de cb2

Info

Publication number
MA38403A1
MA38403A1 MA38403A MA38403A MA38403A1 MA 38403 A1 MA38403 A1 MA 38403A1 MA 38403 A MA38403 A MA 38403A MA 38403 A MA38403 A MA 38403A MA 38403 A1 MA38403 A1 MA 38403A1
Authority
MA
Morocco
Prior art keywords
pyrazole derivatives
modulators specific
new pyrazole
derivatives modulators
new
Prior art date
Application number
MA38403A
Other languages
English (en)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38403A1 publication Critical patent/MA38403A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne un composé représenté par la formule (i) dans laquelle a1 à a3 et r1 à r3 sont tels que définis dans la description et dans les revendications. Le composé de formule (i) peut être utilisé comme médicament.
MA38403A 2013-03-07 2014-03-04 Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 MA38403A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13158233 2013-03-07
PCT/EP2014/054107 WO2014135507A1 (fr) 2013-03-07 2014-03-04 Nouveaux dérivés de pyrazole

Publications (1)

Publication Number Publication Date
MA38403A1 true MA38403A1 (fr) 2017-11-30

Family

ID=47827068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38403A MA38403A1 (fr) 2013-03-07 2014-03-04 Nouveaux dérivés de pyrazole modulateurs specifiques de cb2

Country Status (35)

Country Link
US (2) US9512132B2 (fr)
EP (1) EP2964646B1 (fr)
JP (2) JP6514119B2 (fr)
KR (2) KR102217297B1 (fr)
CN (1) CN105143220B (fr)
AR (1) AR094978A1 (fr)
AU (1) AU2014224784B2 (fr)
BR (1) BR112015020795B1 (fr)
CA (1) CA2897513C (fr)
CL (1) CL2015002387A1 (fr)
CR (1) CR20150447A (fr)
CY (1) CY1118950T1 (fr)
DK (1) DK2964646T3 (fr)
EA (1) EA027935B1 (fr)
ES (1) ES2629751T3 (fr)
HK (1) HK1213258A1 (fr)
HR (1) HRP20170919T1 (fr)
HU (1) HUE034831T2 (fr)
IL (1) IL240327B (fr)
LT (1) LT2964646T (fr)
MA (1) MA38403A1 (fr)
MX (1) MX363727B (fr)
MY (1) MY176797A (fr)
NZ (1) NZ710052A (fr)
PE (1) PE20151539A1 (fr)
PH (1) PH12015501843A1 (fr)
PL (1) PL2964646T3 (fr)
PT (1) PT2964646T (fr)
RS (1) RS56148B1 (fr)
SG (1) SG11201507168XA (fr)
SI (1) SI2964646T1 (fr)
TW (1) TWI609866B (fr)
UA (1) UA118666C2 (fr)
WO (1) WO2014135507A1 (fr)
ZA (1) ZA201505073B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2964646T3 (pl) * 2013-03-07 2017-09-29 F.Hoffmann-La Roche Ag Nowe pochodne pirazolu
BR112015024272A2 (pt) 2013-03-26 2017-07-18 Hoffmann La Roche novos derivados de piridina
ES2680935T3 (es) 2013-05-02 2018-09-11 F. Hoffmann-La Roche Ag Derivados de purina como agonistas del receptor CB2
LT2991988T (lt) 2013-05-02 2017-08-10 F. Hoffmann-La Roche Ag Pirol[2,3-d]pirimidino dariniai kaip cb2 receptorių agonistai
HUE041760T2 (hu) 2013-09-06 2019-05-28 Hoffmann La Roche Triazolo[4,5-d]pirimidin-származékok mint CBb2-receptor antagonisták
MX2017011652A (es) * 2015-03-13 2018-02-09 Abbvie Inc (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.
WO2016191935A1 (fr) * 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Composés 6-alkyle dihydropyrazolopyrimidinone utilisés en tant qu'inhibiteurs de pde2
WO2016192083A1 (fr) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Composés dihydropyrazolopyrimidinone utilisés en tant qu'en tant qu'inhibiteurs de pde2
EP3475283B1 (fr) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine
CR20180615A (es) 2016-06-23 2019-03-05 Hoffmann La Roche Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina
EP3475280B1 (fr) 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Nouvelles dérivés de [1,2,3]triazolo[4,5-d]pyrimidine
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
US20220170826A1 (en) 2019-03-25 2022-06-02 Nikon Corporation Cell manipulation device and cell manipulation method
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980677A (en) * 1961-04-18 Certificate of correction
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2479744A1 (fr) 2002-03-28 2003-10-09 Paul E. Finke 2,3-diphenyl-pyridines substituees
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
US20100227845A1 (en) 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2010118367A2 (fr) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EP2870139B1 (fr) 2012-07-04 2016-06-15 F.Hoffmann-La Roche Ag Nouveaux dérivés adamantyles comme agonistes du récepteur cannabinoïde 2
MX2015007155A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Nuevos derivados de piridina.
IN2015DN03145A (fr) 2012-12-07 2015-10-02 Hoffmann La Roche
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
PE20151089A1 (es) 2012-12-07 2015-08-06 Hoffmann La Roche Piridin-2-amidas utiles como agonistas de cb2
PL2964646T3 (pl) * 2013-03-07 2017-09-29 F.Hoffmann-La Roche Ag Nowe pochodne pirazolu

Also Published As

Publication number Publication date
CL2015002387A1 (es) 2016-03-04
MX363727B (es) 2019-04-01
SI2964646T1 (sl) 2017-08-31
EP2964646B1 (fr) 2017-04-19
JP2016510054A (ja) 2016-04-04
PH12015501843B1 (en) 2015-12-07
DK2964646T3 (en) 2017-07-10
IL240327B (en) 2019-01-31
PL2964646T3 (pl) 2017-09-29
SG11201507168XA (en) 2015-10-29
KR20210019578A (ko) 2021-02-22
NZ710052A (en) 2020-09-25
KR102369407B1 (ko) 2022-03-02
CN105143220A (zh) 2015-12-09
PH12015501843A1 (en) 2015-12-07
JP2019055986A (ja) 2019-04-11
LT2964646T (lt) 2017-07-10
HUE034831T2 (en) 2018-03-28
CR20150447A (es) 2015-10-08
HK1213258A1 (zh) 2016-06-30
US20170035769A1 (en) 2017-02-09
AU2014224784B2 (en) 2018-03-08
EA201591624A1 (ru) 2016-01-29
US9694012B2 (en) 2017-07-04
HRP20170919T1 (hr) 2017-09-22
CN105143220B (zh) 2018-06-22
KR20150126355A (ko) 2015-11-11
BR112015020795A2 (pt) 2017-07-18
PE20151539A1 (es) 2015-10-28
PT2964646T (pt) 2017-06-29
AU2014224784A1 (en) 2015-07-23
ES2629751T3 (es) 2017-08-14
KR102217297B1 (ko) 2021-02-22
TW201506023A (zh) 2015-02-16
EP2964646A1 (fr) 2016-01-13
ZA201505073B (en) 2016-07-27
CA2897513C (fr) 2021-03-16
JP6514119B2 (ja) 2019-05-15
US20150376192A1 (en) 2015-12-31
US9512132B2 (en) 2016-12-06
WO2014135507A1 (fr) 2014-09-12
IL240327A0 (en) 2015-09-24
RS56148B1 (sr) 2017-11-30
TWI609866B (zh) 2018-01-01
CA2897513A1 (fr) 2014-09-12
EA027935B1 (ru) 2017-09-29
MY176797A (en) 2020-08-21
UA118666C2 (uk) 2019-02-25
AR094978A1 (es) 2015-09-09
BR112015020795B1 (pt) 2022-08-16
CY1118950T1 (el) 2018-01-10
MX2015011534A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA38555B1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
MA38432A1 (fr) Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA34078B1 (fr) Derives d'arylethynyle
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31596B1 (fr) Nouveaux herbicides
MA35245B1 (fr) Pyridin-2-amides utiles comme agonistes de cb2
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MA31597B1 (fr) Nouveaux herbicides
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques